$ANGO News

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

AngioDynamics to Participate in Upcoming Investor Conferences

AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics: NanoKnife Momentum Looks Real, But Much Of The Good News Is Priced In

HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19

AngioDynamics, Inc. Q4 2026 Earnings Call Summary

Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20

AngioDynamics Inc (ANGO) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges

AngioDynamics Q4 Earnings Call Highlights

AngioDynamics (NASDAQ:ANGO) Surges on Strong Quarterly Beat as Med Tech Segment Drives Growth

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics Tops Revenue Forecasts and Raises Sales Outlook for Fiscal 2027 (ANGO)

AngioDynamics: Fiscal Q4 Earnings Snapshot

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

Full Transcript: AngioDynamics Q4 2026 Earnings Call

AngioDynamics, Inc. 2026 Q4 - Results - Earnings Call Presentation

AngioDynamics Sees FY2027 Adj EPS $(0.29)-$(0.24) vs $(0.16) Est; Sees Sales $336.000M-$341.000M vs $329.600M Est

AngioDynamics Q4 Adj. EPS $(0.07) Beats $(0.09) Estimate, Sales $86.607M Beat $80.400M Estimate